Terazosin hydrochloride

C₁₉H₂₅N₅O₄ · HCl

423.89

MFCD00467965

24278740

NA.77

Terazosin hydrochloride is used to treat hypertension and benign prostatic hyperplasia (BPH). It is metabolised in the liver. It might be associated with dizziness, headache and asthenia. Terazosin hydrochloride is linked to acute generalized exanthematous pustulosis.

Terazosin hydrochloride has been used for orthogonality and similarity analysis using reversed-phase chromatographic studies⁵. Furthermore, terazosin has also been used for the evaluation of chemometric techniques to determine orthogonality and similarity in chromatographic methods⁶.

α₁-adrenoceptor antagonist.

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Terazosin hydrochloride is soluble in water at 19.60 - 20.40 mg/ml and yields a clear, colorless to faint yellow solution. It is also soluble in ethanol at 4 mg/ml. Furthermore, the product is soluble in methanol at 20 mg/ml, with heat as needed, and yields a clear, colorless solution.

200

≥98% (TLC)

powder

white to off-white

H₂O: soluble 19.60-20.40 mg/mL, clear, colorless to faintly yellow
methanol: 20 mg/mL, clear, colorless
ethanol: 4 mg/mL

Abbott

Cl[H].COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4

1S/C19H25N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H

IWSWDOUXSCRCKW-UHFFFAOYSA-N

human ... ADRA1A(148), ADRA1B(147), ADRA1D(146)

250 mg in glass bottle
50 mg in poly bottle

GHS07

Warning

H302

P264 - P270 - P301 + P312 - P501

Acute Tox. 4 Oral

11 - Combustible Solids

WGK 3

dust mask type N95 (US), Eyeshields, Gloves